Page 85 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

Overview of Primary and Secondary Vasculitides 61

[211] Torvik, A., Berntzen, A. E. Necrotizing vasculitis without visceral involvement.
Postmortem examination of three cases with affection of skeletal muscles and
peripheral nerves. Acta Med. Scand. 1968; 184:69-77.

[212] Younger, D. S. Diabetic neuropathy: A clinical and neuropathological study of 107
patients. Neurol. Res. Int. 2010, Article ID: 140379.

[213] Kissel, J. T., Slivka, A. P., Warmolts, J. R., Mendell, J. R. The clinical spectrum of
necrotizing angiopathy of the peripheral nervous system. Ann. Neurol. 1985; 18:251-
257.

[214] Said, G., Lacroix-Ciaudo, C., Fujimura, H., et al. The peripheral neuropathy of
necrotizing arteritis: A clinicopathologic study. Ann. Neurol. 1988; 23:461-465.

[215] Collins, M. P., Periquet, M. I., Mendell, J. R., et al. Nonsystemic vasculitis neuropathy.
Insights from a clinical cohort. Neurology 2003; 61:623-630.

[216] Hoffman, G. S. Vasculitis treatment: is it time to change the standard of care for
ANCA-associated vasculitis? Presse Med. 2013; 42:643-650.

[217] Lyons, P. A., Rayner, T. F., Trivedi, S., et al. Genetically distinct subsets within
ANCA-associated vasculitis. N. Engl. J. Med. 2012; 367:214-223.

[218] Jones, R. B., Tervaert, J. W., Hauser, T., et al., for the European Vasculitis Study
Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N.
Engl. J. Med. 2010; 363:211-220.

[219] Ludviksson, B. R., Sneller, M. C., Chua, K. S., et al. Active Wegener?s granulomatosis
is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type cytokine
pattern: reversal with IL-1-. J. Immunol. 1998; 160:3602-3609.

[220] Noronha, I. L., Kruger, C., Andrassy, K., et al. In situ production of TNF-alpha, IL-1
beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int. 1993; 43:682-692.

[221] Wegener?s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus
standard therapy for Wegener?s granulomatosis. N. Engl. J. Med. 2005; 352:351-361.

[222] De Groot, K., Rasmussen, N., Bacon, P. A., et al., for the European Vasculitis Study
Group. Randomized trial of cyclophosphamide versus methotrexate for induction of
remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
Arthritis Rheum. 2005; 52:2461-2469.

[223] Alba, M. A., Flores-Suárez, L. F. Seven clinical conundrums in the treatment of
ANCA-associated vasculitis. Clin. Exp. Rheumatol. 2013; 31(1 Suppl. 75):S74-S83.

[224] Chaigne, B., Gatault, P., Darrouzain, F., et al. Mycophenolate mofetil in patients with
anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective
pharmacokinetics and clinical study. Clin. Exp. Immunol. 2014; 176:172-179.

[225] Jayne, D., Rasmussen, N., Andrassay, K., et al., for the European Vasculitis Study
Group. A randomized trial of maintenance therapy for vasculitis associated with
antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 2003; 349:36-44.

[226] Hiemstra, T. F., Walsh, M., Mahr, et al., for the European Vasculitis Study Group
(EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in
antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.
JAMA 2010; 304:2381-2388.

[227] Jayne, D. Treating vasculitis with conventional immunosuppressive agents. Cleve. Clin.
J. Med. 2012; 79(Suppl. 3):S46-S49.

[228] Dalakas, M. C. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
JAMA 2004; 291:2367-2375.

Complimentary Contributor Copy